Tacrolimus: the good, the bad, and the ugly

Area of Science:

• Pediatric Transplant Medicine
• Immunosuppression Therapy

Background:

• Pediatric transplant recipients often require immunosuppression to prevent rejection.
• Cyclosporin A (CsA) is a common immunosuppressant, but can be associated with side effects and refractory rejection.
• Tacrolimus offers an alternative immunosuppressive agent with a different efficacy and side-effect profile.

Purpose of the Study:

• To evaluate the efficacy and safety of switching from Cyclosporin A (CsA) to tacrolimus in pediatric transplant patients.
• To assess the impact of tacrolimus conversion on organ function, rejection rates, and side effects.
• To identify potential complications associated with tacrolimus therapy in this population.

Main Methods:

• Retrospective chart review of 11 pediatric cardiac or renal transplant patients converted from CsA to tacrolimus.
• Analysis of organ function (creatinine, biopsy, catheterization) pre- and post-conversion.
• Patient and parent interviews to gather data on transplant history, medications, and adverse events.

Main Results:

• Seven of eight patients treated for rejection showed improvement after conversion to tacrolimus.
• Four patients were successfully weaned off steroid therapy, promoting growth potential.
• Reported side effects included transient hyperglycemia, headaches, and tremors; two patients progressed to chronic rejection.
• Four patients developed post-transplant lymphoproliferative disease (PTLD), which was managed with dose reduction or surgery.

Conclusions:

• Tacrolimus is an effective alternative for managing refractory rejection in pediatric transplant recipients.
• Conversion to tacrolimus can facilitate steroid withdrawal, potentially improving long-term outcomes.
• Careful monitoring for PTLD is essential due to its serious nature and potential association with tacrolimus therapy.